J
Julius J. Deren
Researcher at University of Pennsylvania
Publications - 31
Citations - 2435
Julius J. Deren is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Inflammatory bowel disease & Malabsorption. The author has an hindex of 18, co-authored 31 publications receiving 2383 citations. Previous affiliations of Julius J. Deren include Walter Reed Army Institute of Research & Reed College.
Papers
More filters
Journal ArticleDOI
Role of oral intake in maintenance of gut mass and disaccharide activity.
TL;DR: It is demonstrated that the physiological responses related to food ingestion are important in maintaining small intestinal mass, disaccharidase activity, and the proximal-distal gradient.
Journal ArticleDOI
Inflammatory bowel disease is not associated with an increased risk of lymphoma
James D. Lewis,Warren B. Bilker,Colleen M. Brensinger,Julius J. Deren,David J. Vaughn,Brian L. Strom +5 more
TL;DR: Patients with inflammatory bowel disease do not have an increased risk of lymphoma as compared with the general population, and a modest increased risk with azathioprine or 6-MP therapy is not observed.
Journal ArticleDOI
National Cooperative Crohn's Disease Study: factors determining recurrence of Crohn's disease after surgery.
Hagop S. Mekhjian,Donald M. Switz,H. David Watts,Julius J. Deren,Ronald M. Katon,Floyd M. Beman +5 more
TL;DR: The site of involvement of Crohn's disease is a major determinant of outcome after surgical intervention, and the data suggest a higher recurrence rate after the second surgery.
Journal ArticleDOI
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.
James D. Lewis,Gary R. Lichtenstein,Julius J. Deren,Bruce E. Sands,Stephen B. Hanauer,Jeffrey Katz,Bret A. Lashner,Daniel H. Present,Shaokun Chuai,Jonas H. Ellenberg,Lisa Nessel,Gary D. Wu +11 more
TL;DR: Rosiglitazone was efficacious in the treatment of mild to moderately active UC and improved quality of life as early as 4 weeks after beginning treatment.
Journal ArticleDOI
Cancer risk in patients with inflammatory bowel disease
TL;DR: This article reviews the current literature relating to the risk of cancer for patients with IBD and methods to reduce this risk and identifies the optimal strategy for reducing this risk.